John Stagg

List of Publications by Year in Descending Order

59 papers	5,738 citations	35 h-index	63 g-index
63 ext. papers	7,154 ext. citations	9.6 avg, IF	6.07 L-index

#	Paper	IF	Citations
59	Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns.. *British Journal of Cancer*, **2022**,	8.7	1
58	Spatially mapping the immune landscape of melanoma using imaging mass cytometry.. *Science Immunology*, **2022**, 7, eabi5072	28	2
57	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer **2021**, 9,		6
56	1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. *Science Advances*, **2021**, 7,	14.3	13
55	Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. *OncoImmunology*, **2020**, 9, 1746138	7.2	6
54	The adenosine pathway in immuno-oncology. *Nature Reviews Clinical Oncology*, **2020**, 17, 611-629	19.4	101
53	Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. *Leukemia*, **2020**, 34, 2708-2721	10.7	14
52	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. *Journal of the National Cancer Institute*, **2020**, 112, 708-719	9.7	45
51	The effect of ultrasound pulse length on microbubble cavitation induced antibody accumulation and distribution in a mouse model of breast cancer. *Nanotheranostics*, **2020**, 4, 256-269	5.6	5
50	Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. *Science*, **2020**, 369, 1481-1489	33.3	233
49	On the mechanism of anti-CD39 immune checkpoint therapy **2020**, 8,		42
48	Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. *OncoImmunology*, **2019**, 8, 1601481	7.2	10
47	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. *OncoImmunology*, **2019**, 8, e1581545	7.2	9
46	Targeting the CD73-adenosine axis in immuno-oncology. *Immunology Letters*, **2019**, 205, 31-39	4.1	73
45	Targeting the adenosine pathway for cancer immunotherapy. *Seminars in Immunology*, **2019**, 42, 101304	10.7	37
44	Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. *Methods in Enzymology*, **2019**, 629, 269-289	1.7	3
43	NR4A Expression by Human Marginal Zone B-Cells. *Antibodies*, **2019**, 8,	7	3

42	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. *Journal of Clinical Investigation*, **2019**, 129, 1785-1800	15.9	125
41	Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. *Annals of Oncology*, **2018**, 29, 1056-1062	10.3	92
40	CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination. *PLoS ONE*, **2018**, 13, e0191973	3.7	2
39	Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.. *Journal of Clinical Oncology*, **2018**, 36, 3584-3584	2.2	2
38	Targeting A2 adenosine receptors in cancer. *Immunology and Cell Biology*, **2017**, 95, 333-339	5	65
37	The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunological Reviews*, **2017**, 276, 121-144	11.3	414
36	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. *Cancer Research*, **2017**, 77, 5652-5663	10.1	64
35	PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. *Cancer Research*, **2017**, 77, 312-319	10.1	21
34	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. *Journal of Clinical Investigation*, **2017**, 127, 929-941	15.9	183
33	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. *Methods in Molecular Biology*, **2016**, 1458, 159-77	1.4	5
32	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. *Biomarkers in Cancer*, **2016**, 8, 15-33	7	57
31	CD73-adenosine: a next-generation target in immuno-oncology. *Immunotherapy*, **2016**, 8, 145-63	3.8	82
30	CD73-adenosine reduces immune responses and survival in ovarian cancer patients. *OncoImmunology*, **2016**, 5, e1127496	7.2	27
29	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 158-66	12.9	121
28	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. *Cancer Research*, **2016**, 76, 4372-82	10.1	94
27	Immunosuppressive activities of adenosine in cancer. *Current Opinion in Pharmacology*, **2016**, 29, 7-16	5.1	156
26	CD73 plays a protective role in collagen-induced arthritis. *Journal of Immunology*, **2015**, 194, 2487-92	5.3	27
25	CD73 is associated with poor prognosis in high-grade serous ovarian cancer. *Cancer Research*, **2015**, 75, 4494-503	10.1	142

24	Immunology and Immunotherapy of Breast Cancer **2015**, 457-470		
23	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. *Cancer Immunology Research*, **2015**, 3, 506-17	12.5	198
22	Abstract 3361: CD73 expression on tumor-infiltrating breast cancer leukocytes **2015**,		2
21	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 863-81	6.4	30
20	Targeting cancer-derived adenosine: new therapeutic approaches. *Cancer Discovery*, **2014**, 4, 879-88	24.4	199
19	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. *Cancer Research*, **2014**, 74, 3652-8	10.1	178
18	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. *OncoImmunology*, **2014**, 3, e958952	7.2	18
17	Anti-CD73 therapy impairs tumor angiogenesis. *International Journal of Cancer*, **2014**, 134, 1466-73	7.5	108
16	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 11091-6	11.5	303
15	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. *Therapeutic Advances in Medical Oncology*, **2013**, 5, 169-81	5.4	121
14	Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 14711-6	11.5	244
13	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. *Clinical Cancer Research*, **2013**, 19, 5626-35	12.9	293
12	CD73-deficient mice are resistant to carcinogenesis. *Cancer Research*, **2012**, 72, 2190-6	10.1	156
11	CD73: a potent suppressor of antitumor immune responses. *Trends in Immunology*, **2012**, 33, 231-7	14.4	253
10	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. *Journal of Biomedicine and Biotechnology*, **2012**, 2012, 485156		64
9	The double-edge sword effect of anti-CD73 cancer therapy. *OncoImmunology*, **2012**, 1, 217-218	7.2	22
8	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. *Breast Care*, **2012**, 7, 267-72	2.4	11
7	CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. *Cancer Research*, **2011**, 71, 2892-900	10.1	297

6	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7142-7	11.5	334
5	Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 1547-52	11.5	413
4	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 16254-9	11.5	40
3	Mesenchymal stem cells in cancer. *Stem Cell Reviews and Reports*, **2008**, 4, 119-24	6.4	81
2	From cancer immunosurveillance to cancer immunotherapy. *Immunological Reviews*, **2007**, 220, 82-101	11.3	70
1	NK cell-based cancer immunotherapy. *Drug News and Perspectives*, **2007**, 20, 155-63		17